Louise Rodino-Klapac - 17 Nov 2023 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Role
Head of R&D, CSO
Signature
/s/ Ryan Brown, as Attorney-in-Fact for Louise Rodino-Klapac
Issuer symbol
SRPT
Transactions as of
17 Nov 2023
Net transactions value
-$374,074
Form type
4
Filing time
20 Nov 2023, 20:00:08 UTC
Previous filing
10 Mar 2023
Next filing
05 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRPT Common Stock Tax liability $374,074 -4,508 -6.4% $82.98 65,751 17 Nov 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on November 16, 2021.
F2 Amount of Securities Beneficially Owned includes 89 shares purchased under the Company's registered Employee Stock Purchase Plan on August 31, 2023.